It began in 2015 with a small extraction rig, a handful of determined colleagues, and a belief that cannabis, done properly, could change British healthcare. Today, that vision has grown into BRITISH CANNABIS®, the UK’s largest cannabinoid manufacturer and, as of this quarter, the most-prescribed medical cannabis oil brand in the country.
Marking its ten-year milestone, the Board has appointed Adam Windish as Chief Executive Officer. Founder Tom Whettem will remain closely involved in a Strategic Advisor role, continuing to support the business as it enters its next phase of growth.
Tom Whettem - “We were a small team fighting to keep CBD legal, packing orders ourselves, taking every customer call, and lobbying Westminster between shifts. To now see doctors across the country choosing our (medicinal cannabis) oils first, that’s the result of a decade of doing things the right way. Adam is the right leader to take it further.”
Adam Windish - “BRITISH CANNABIS® has always been about integrity, consistency, and care. My role now is to scale what’s already working, expanding access, strengthening the evidence base, and staying focused on safety and quality for every patient, customer, and business who relies on our products.”
With this leadership transition, a number of positive internal changes have been made to support the company’s long-term ambitions. It is very much business as usual, with plenty of exciting developments on the horizon.
We would also like to take this opportunity to thank our loyal customers and partners for their continued support over the years. Your trust has been central to our success, and we remain committed to supporting your needs for the next decade and beyond. A Decade in Three Milestones:
- 2016 – Standing Firm When regulators threatened to ban CBD, Whettem co-founded the Cannabis Trades Association (CTA) and helped secure a legal, compliant future for the sector.
- 2022 – Building Scale With over 1,470 products listed on the FSA’s (Food Standards Agency UK) novel foods register, BRITISH CANNABIS ® became the UK’s largest compliant cannabinoid manufacturer.
- 2025 – Clinicians’ Choice Q1 audits from leading private clinics and specialist pharmacies confirm BRITISH CANNABIS® Medicines as the most prescribed medical cannabis oil brand in the UK.
Expanding Medical Without Losing Our Roots
While BRITISH CANNABIS® built its reputation on award-winning over-the-counter CBD products, the company has always had a clear long-term vision: to become a trusted, full-spectrum cannabis business. The success of its medical division marks a natural evolution, combining its regulatory expertise and quality-first approach to now serve both consumer wellness and clinical care with the same commitment to excellence.
Looking Ahead Product Development: New formulations and delivery formats currently in development, with further launches targeted for late 2025.
Digital Health: The updated Canndr® platform goes live this autumn, offering real-time formulary access, integrated prescribing tools, and a patient-centred marketplace where individuals can purchase everything they need, from high-quality CBD to medically approved vaporisers for their prescriptions.
Global Reach: Licensing discussions underway across EU and APAC regions under the “Powered by BRITISH CANNABIS®” model.
About BRITISH CANNABIS® Founded in 2015, BRITISH CANNABIS® operates a full seed-to-shelf supply chain including high quality bespoke manufacturing including GMP-certified manufacturing and accredited analytics. From over-the-counter CBD to prescribed cannabis medicines, the company sets the benchmark for safety, transparency, and therapeutic value in the UK and beyond.
Visit: britishcannabis.org
Media Enquiries: info@britishcannabis.org
Sales Enquiries trade@britishcannabis.org
BCM Scientific Ltd, trading as BRITISH CANNABIS® | Company No. 15352957
Find out more about BRITISH CANNABIS™ on their member profile page here
Member-created content 1 week ago | From members